Log in
Enquire now
‌

US Patent 11279694 Alvocidib prodrugs and their use as protein kinase inhibitors

Patent 11279694 was granted and assigned to Sumitomo Dainippon Pharma Oncology on March, 2022 by the United States Patent and Trademark Office.

OverviewStructured DataIssuesContributors

Contents

Is a
Patent
Patent
0

Patent attributes

Patent Applicant
‌
Sumitomo Dainippon Pharma Oncology
0
Current Assignee
‌
Sumitomo Dainippon Pharma Oncology
0
Patent Jurisdiction
United States Patent and Trademark Office
United States Patent and Trademark Office
0
Patent Number
112796940
Patent Inventor Names
Wataru Hirose0
Yusuke Sawayama0
Adam Siddiqui-Jain0
Hitoshi Ban0
Date of Patent
March 22, 2022
0
Patent Application Number
164620940
Date Filed
November 17, 2017
0
Patent Citations
‌
US Patent 10357488 Predicting response to alvocidib by mitochondrial profiling
0
‌
US Patent 10422788 Profiling peptides and methods for sensitivity profiling
‌
US Patent 10562925 Alvocidib prodrugs having increased bioavailability
‌
US Patent 10568887 Combination therapies for treatment of cancer
‌
US Patent 10624880 Predicting response to alvocidib by mitochondrial profiling
‌
US Patent 10793915 Context dependent diagnostics test for guiding cancer treatment
0
‌
US Patent 10682356 Combination therapies for treatment of cancer
‌
US Patent 10835537 Combination therapies for treatment of cancer
...
Patent Citations Received
‌
US Patent 12077554 CDK9 inhibitors and polymorphs thereof for use as agents for treatment of cancer
0
‌
US Patent 11530231 CDK9 inhibitors and polymorphs thereof for use as agents for treatment of cancer
0
‌
US Patent 11497756 Treatment regimen for cancers that are insensitive to BCL-2 inhibitors using the MCL-1 inhibitor alvocidib
Patent Primary Examiner
‌
Nizal S Chandrakumar
0
CPC Code
‌
C07D 405/04
0
Patent abstract

Compounds having the following structure (I) or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof, wherein R1, R2 and R3 are as defined herein, and wherein at least one of R1, R2 and R3 is not H, are provided. Pharmaceutical compositions comprising the compounds and methods for use of the compounds for treating diseases associated with overexpression of a cyclin-dependent kinase (CDK) are also provided.

Timeline

No Timeline data yet.

Further Resources

Title
Author
Link
Type
Date
No Further Resources data yet.

References

Find more entities like US Patent 11279694 Alvocidib prodrugs and their use as protein kinase inhibitors

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
Open Query Tool
Access by API
Golden Query Tool
Golden logo

Company

  • Home
  • Press & Media
  • Blog
  • Careers
  • WE'RE HIRING

Products

  • Knowledge Graph
  • Query Tool
  • Data Requests
  • Knowledge Storage
  • API
  • Pricing
  • Enterprise
  • ChatGPT Plugin

Legal

  • Terms of Service
  • Enterprise Terms of Service
  • Privacy Policy

Help

  • Help center
  • API Documentation
  • Contact Us
By using this site, you agree to our Terms of Service.